Navigation Links
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Date:8/6/2009

to $63,961,000 as of March 31, 2009.

"We are pleased to have advanced our pipeline programs this quarter, and we expect to receive pivotal data from both our Phase 3 pancreatic imaging and Phase 2b bipolar depression studies in 2010," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Our financial resources will allow us to continue to pursue our goal to build a sustainable biopharmaceutical company by developing innovative products that have the potential to markedly improve patients' lives."

Corporate Update

RG1068 for Imaging of the Pancreas

We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, designed to assess the ability of RG1068 in combination with magnetic resonance imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment of diseases such as acute and chronic pancreatitis. This study is being conducted at approximately 30 clinical sites within the U.S. and Canada and will enroll approximately 225 patients. We have made steady progress on enrollment and plan to complete this trial by the end of the year. The FDA has granted this program Fast Track Designation, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could benefit from the use of RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depressi
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... DUBLIN , July 28, 2014 Research ... "Global Particle Size Analysis Market 2014-2018" report to their ... Particle size analysis is a technique used to determine ... powder or liquid. It is crucial to analyze the size ... material. Therefore, particle size analysis is performed to determine the ...
(Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
(Date:7/25/2014)... July 25, 2014 The Conferee Networking ... Topics for Conferee Networking. These two-hour sessions provide a ... meet and resolve problems, discuss new techniques, or brainstorm ... to submit a topic for consideration is August 31, ... . The Conferee Networking committee will review the topics, ...
(Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
Breaking Biology Technology:Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... MINNEAPOLIS and ST. PAUL, Minn., Dec. 11 The ... diabetes research from the,Richard M. Schulze Family Foundation. Goals ... capitalize on the University,s strength in diabetes,research and to accelerate ... with type 1 diabetes. , ...
... Seed Companies to Introduce New Products, Brands. , ... ... Hi-Bred today unveiled a new business strategy to bring its ... of partnerships and new brands. , , , , ,The strategy, ...
... THOUSAND OAKS, Calif., Dec. 11 Ceres, Inc. announced ... seed under its,Blade Energy Crops label. The highly anticipated ... developed specifically as raw materials,for biofuels and biopower. The ... , The company ...
Cached Biology Technology:University of Minnesota Receives $40 Million for Type 1 Diabetes Research 2University of Minnesota Receives $40 Million for Type 1 Diabetes Research 3University of Minnesota Receives $40 Million for Type 1 Diabetes Research 4DuPont Unveils New Strategy to Expand its Seed Business 2DuPont Unveils New Strategy to Expand its Seed Business 3DuPont Unveils New Strategy to Expand its Seed Business 4First Seed Sales of Dedicated Energy Crops Begin 2First Seed Sales of Dedicated Energy Crops Begin 3
(Date:7/25/2014)... of biomedical engineering at the University of Houston, ... and artificial organ development., "Introduction to Tissue Engineering: ... entering into the field of artificial organ development. ... engineering at UH, served as a series editor ... are other published books on the subject of ...
(Date:7/25/2014)... of Adelaide has opened the way for the development of ... In Australia, annual barley production is second only to wheat ... of the most important diseases of barley. , Senior Research ... of special growths on the cell walls of barley plants ... , The research, by the ARC Centre of Excellence in ...
(Date:7/25/2014)... complex congenital central nervous system disease that is ... tubes during the embryonic phase. Many patients have ... and neurocognitive retardation. Such problems decrease the patients, ... at Ankara Physical Medicine and Rehabilitation Education and ... children with SB, using the Pediatric Evaluation of ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... hospital gowns and bed sheets to match a patient,s skin ... and other health-related skin color changes, according to a new ... a patient, and then sees the patient again later, the ... skin has changed color," said neurobiologist and study leader Mark ...
... The U.S. Environmental Protection Agency (EPA) is making ... releasing a database, called ToxRefDB, which allows scientists and ... toxicity testing results on hundreds of chemicals. ToxRefDB captures ... "Tens of thousands of chemicals are in commerce and ...
... available in German . 48 healthy males participated ... start of the experiment, the other half a placebo. The researchers ... the form of a crying child, a girl hugging her cat, ... express the depth of feeling they experienced for the persons shown. ...
Cached Biology News:Nude-colored hospital gowns could help doctors better detect hard-to-see symptoms 2US Environmental Protection Agency opens access to chemical information 2Hormone spray improves male sensitivity 2
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
A trigger solution for Flashlight labeled materials....
... mobility shift assay (EMSA) is a powerful ... to as gel shift or gel retardation, ... that when subjected to electrophoresis, free DNA ... The Pierce LightShift Chemiluminescent EMSA Kit is ...
Biology Products: